Bronchogen
- Status
- Preclinical, , not approved for human use
- Evidence
Not graded on a research bench yet
Bronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "bronchial bioregulator" intended to support respiratory epithelium and ciliated-airway function in chronic obstructive pulmonary disease (COPD), chronic bronchitis, and age-related decline of mucociliary clearance.
Reviewed
01Overview
What Bronchogen is
It is usually described in Khavinson-family publications as the tetrapeptide Ala-Glu-Asp-Pro (AEDP), sometimes written H-Ala-Glu-Asp-Pro-OH or A-E-D-P. It sits alongside Pinealon, Thymogen, Vilon, Epitalon, and Livagen within the Khavinson short-peptide bioregulator family, and it is the defined-sequence counterpart to a polypeptide preparation called Chonluten that is prepared from bovine bronchial mucosa — a relationship that mirrors the Thymogen/Thymalin and Livagen/Stamakort pattern throughout the bioregulator programme.
Read the full overviewShow less
Outside Russia and a small handful of former-Soviet pharmacology journals, Bronchogen is not a registered drug, not an FDA- or EMA-reviewed supplement, and not a member of the WADA Prohibited List. There are no phase II or phase III randomised trials indexed in PubMed or ClinicalTrials.gov, and the peptide does not appear in GOLD, ERS, or NICE guidelines for COPD or chronic bronchitis. The published Russian work — most of it authored or co-authored by Khavinson and colleagues, with occasional collaborators in Almaty and Minsk — comprises in vitro cell-culture experiments in bronchial epithelial cells, small rodent studies of induced lung injury, and a handful of uncontrolled observational case series in elderly patients with chronic respiratory disease ([Khavinson et al., 2011]; [Chalisova et al., 2015]; [Kuznik et al., 2011]).
The central claim made for Bronchogen is the standard Khavinson short-peptide model applied to the bronchial epithelium: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation that preferentially up-regulates genes associated with epithelial regeneration, mucociliary function, and surfactant production. The specific-tissue selectivity claim — that AEDP targets bronchial rather than hepatic or pineal tissue — is not supported by structural biology or by modern biodistribution studies, and rests on extrapolation from the aggregate Khavinson framework. The hypothesis is internally consistent within the Khavinson programme; it is also substantially less validated than the pharmacology of even moderately well-studied respiratory drugs.
BodyHackGuide covers Bronchogen because it is sold online in post-Soviet supplement channels (typically as 20 mg oral capsules containing an undisclosed quantity of actual peptide) and because it shows up in longevity-stack discussions where the speaker frames it as a respiratory-support bioregulator alongside proven interventions. We describe what is known, what is claimed, and what is missing — and we steer readers who want evidence-graded respiratory support toward interventions with substantial replication: smoking cessation, pulmonary rehabilitation, inhaled bronchodilators and corticosteroids for obstructive disease, GLP-1 agonist-mediated weight loss for obesity-related restrictive disease, and, where specifically indicated, biologics such as benralizumab, mepolizumab, or dupilumab. Bronchogen is a plausible hypothesis. It is not, in 2026, an evidence-graded respiratory therapy.
How it works
Mechanism of Action
Bronchogen's proposed mechanism is the standard Khavinson short-peptide bioregulator model applied to bronchial and respiratory epithelium. The framework, developed at the St. Petersburg Institute of Bioregulation and Gerontology across roughly three decades, proposes a three-stage mechanism: passive membrane permeation, nuclear import by diffusion, and sequence-selective chromatin interaction producing tissue-appropriate gene expression changes.
Read the full mechanismShow less
Step 1 - Absorption and distribution. At approximately 446.45 g/mol (H-Ala-Glu-Asp-Leu-OH), Bronchogen is small and sufficiently polar to cross phospholipid bilayers passively. Khavinson's tritiated peptide biodistribution studies - conducted across multiple tetrapeptides with shared methodology - reported rapid tissue uptake after intraperitoneal or oral dosing, with radioactive label recovered from lung, liver, brain, and thymus within minutes ([Khavinson et al., 2014]). Those experiments did not separate intact peptide from catabolite pools, so the claim that Bronchogen delivers intact AEDL to bronchial epithelial nuclei rests on inference rather than direct structural confirmation.
Step 2 - Bronchial targeting. The Khavinson-framework claim is that AEDL shows tissue-preferential uptake in bronchial tissue, explaining the respiratory-selective pharmacological effect. The supporting data are radiolabel-uptake measurements in bulk tissue homogenates. Modern biodistribution methods - LC-MS/MS intact-peptide quantification, immuno-histochemistry on a dose-matched vehicle control, single-cell transcriptomics on airway epithelium after dosing - have not been applied to Bronchogen in English-indexed literature. Whether the bronchial selectivity is real, artefactual, or simply a product of the Khavinson-framework narrative is open.
Step 3 - Chromatin modulation. Once inside the bronchial epithelial cell, the Khavinson framework proposes that AEDL diffuses through nuclear pores and makes sequence-selective contacts with exposed DNA regions and histone tails. The proposed consequence is preferential decondensation of silenced chromatin regions carrying genes associated with epithelial regeneration - ciliogenesis, surfactant production, tight-junction proteins, mucin transcription programmes. Russian in vitro work reports that Bronchogen tissue-specifically upregulates differentiation markers (CXCL12, Hoxa3) in aging human bronchial epithelial cell cultures (Khavinson et al., 2012). The data do not rise to the level of genome-wide ChIP-seq, ATAC-seq, or CUT&RUN - methods that have not been applied to short Khavinson peptides in any published work.
Alternative conservative framing. A more conservative mechanistic interpretation treats Bronchogen as a mixture of four amino acids (alanine, glutamate, aspartate, leucine) delivered in a rapidly absorbed short-peptide form. In that framing, biological effects observed in Russian studies could reflect substrate delivery for protein synthesis in rapidly turning-over epithelium, non-specific signalling effects of individual amino acids (leucine as a branched-chain amino acid and mTOR-pathway activator that drives protein synthesis, glutamate as an excitatory signal in chemosensory systems), or simple supportive nutrition to tissue under stress. Under this framing, any amino-acid mixture delivered via comparable route would be mechanistically equivalent - which makes the specificity claim for AEDL unlikely to survive rigorous pharmacological testing.
Receptor pharmacology. No G-protein-coupled receptor, nuclear receptor, or defined enzyme target has been identified for Bronchogen. It does not bind 2-adrenoceptors (the molecular target of salbutamol and formoterol), muscarinic receptors (the target of tiotropium), leukotriene receptors, or any of the well-characterised signalling pathways in airway smooth muscle and epithelium. The absence of a defined target is the hallmark of the Khavinson framework - bioregulators are claimed to act through chromatin - but it also explains why Western respiratory pharmacology has not adopted the compound.
Relation to other Khavinson peptides. Bronchogen is the defined-sequence analogue of Chonluten, a bovine-bronchial polypeptide extract sold as a parallel bioregulator product. Both are positioned as respiratory bioregulators; Bronchogen is the synthetic, chemically-characterised short peptide while Chonluten is the undefined natural extract. This dual positioning - a polypeptide "parent" and a short-peptide "sibling" - repeats throughout the Khavinson programme and reflects a conscious strategy to produce pure, defined-composition alternatives to the original extract-based bioregulators. Whether the strategy succeeds in reproducing biological effects is the open question.
Comparison to evidence-graded respiratory mechanisms. Inhaled 2-agonists cause bronchodilation through smooth-muscle relaxation via G-protein signalling (measured, quantified, structurally mapped). Inhaled corticosteroids suppress eosinophilic airway inflammation through glucocorticoid receptor activation (RCT-validated, mechanism understood to molecular detail). Muscarinic antagonists block parasympathetic bronchoconstriction (mapped to M3 receptor occupancy). Mucolytic agents (NAC, carbocysteine) alter mucin disulphide chemistry directly (chemistry understood). Bronchogen, even if it works as claimed, sits at a completely different level of mechanistic specification - it is a hypothesis about chromatin, not a measured pharmacological tool.
Benefits listed
- Respiratory tissue repair
- Improved bronchial function
- Support for chronic respiratory conditions
- Mucosal membrane normalization
02Research
Free with emailWhat the research shows
No research bench grades Bronchogen yet. Benches compare compounds people pair, with the evidence for each.
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
03Safety
Bronchogen side effects and interactions
Side effects
Not in our record
Who should not use it
Contraindications
Contraindications
Bronchogen is an investigational Russian bioregulator. Contraindications reflect clinical prudence rather than a formally studied adverse-event database.
Read all the contraindications and cautionsShow less
Absolute contraindications
- Pregnancy — no reproductive toxicology data
- Breastfeeding — no excretion/infant safety data
- Paediatric use (under 18) — unquantified developmental effects
- Active lung cancer or recent history — chromatin-modulation claim not safe in proliferative lung disease
- Known hypersensitivity to Bronchogen or any Khavinson bioregulator peptide
Relative contraindications (use only with clinical supervision)
- Severe COPD (GOLD stage 3–4, FEV1 <50% predicted) — pulmonology management, not experimental peptides
- Pulmonary fibrosis (idiopathic or known cause) — anti-fibrotic evidence-based therapy (nintedanib, pirfenidone) should not be delayed
- Pulmonary hypertension — coordinated care with specialist
- Active tuberculosis — specific anti-TB therapy, not experimental bioregulators
- Active pneumonia or bacterial exacerbation — appropriate antibiotic therapy required
- Home oxygen therapy — advanced respiratory disease, work with pulmonologist
Use with caution
- Asthma on biologic therapy (benralizumab, mepolizumab, dupilumab, tezepelumab) — no interaction data, coordinate with specialist
- COPD on triple inhaler therapy — no interaction data expected but unreported
- Smokers — Bronchogen does not substitute for smoking cessation; using it as an excuse to continue smoking is actively harmful
- Occupational lung disease — silicosis, asbestosis, hypersensitivity pneumonitis — specific disease management required
- Solid organ transplant recipients — immunosuppression balance, experimental peptides inappropriate
Quality-of-supply contraindication
Do not use Bronchogen from a vendor without third-party HPLC peptide content confirmation and endotoxin testing. Grey-market peptide supply is not uniform. Cheap unverified product is not worth the cost savings.
Symptoms that suggest needing evaluation, not bioregulators
New dyspnoea, haemoptysis, unexplained weight loss, night sweats, persistent cough over 3 weeks, fever, or chest pain are indications for prompt medical evaluation rather than Bronchogen self-treatment. Do not use an experimental bioregulator as a substitute for diagnostic workup of symptomatic respiratory disease.
Interactions
1 pairing in our record: 1 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.
Chonluten
SynergisticBronchogen for lungs + Chonluten for related mucosal tissue — complementary respiratory support
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Need bloodwork before starting?
Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.
04Dosing
Free with emailBronchogen dosage and protocols
- Dose range
- 20 mg oral capsule once daily, 10-day cycles
- Dosing
- Once daily
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- Dose, how often and how long
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
- Stacking notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
05Prices
Bronchogen prices
1 listing from 1 vendor, opening in the Featured order.
- Pack prices
- $79.00
- Lowest per mg
- $3.95/mg
- Vendors
- 1
- Listings
- 1 (vial)
Prices as the vendors list them, last recorded 22 April 2026.
| Vendor | Product | Price | Buy |
|---|---|---|---|
Bronchogen 20mg vial, 1 vial In stock | $3.95/mg $79.00 Lowest per mg | Buy Bronchogen 20mg at Ion Peptide |
Vendors selling Bronchogen(1: trust score, certificates, payment, shipping)
- Ion Peptide1 listing, from $79.00
Trust Score 70/100, no certificate records on file, pays by card, crypto, ACH, ships to the US, international destinations
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors
06Chemistry
Chemistry and structure
- Molecular formula
- C18H30N4O9
- Molecular mass
- 446.45 g/mol
- IUPAC name
- L-Alanyl-L-glutamyl-L-aspartyl-L-leucine
- Amino acid sequence
- Ala-Glu-Asp-Leu (AEDL)
- Half-life
- Not established (no published human pharmacokinetic data; rapid enzymatic hydrolysis within minutes is expected for a tetrapeptide of this class)
08Questions
Frequently asked questions
What is Bronchogen and what is it claimed to do?
Bronchogen is a synthetic tetrapeptide (Ala-Glu-Asp-Leu, AEDL) developed by Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology as a respiratory bioregulator. It is positioned as a support for bronchial epithelium regeneration, mucociliary clearance, and respiratory function in elderly patients with chronic obstructive pulmonary disease, chronic bronchitis, and post-infective respiratory dysfunction. Russian literature reports in vitro effects on bronchial epithelial cultures - the peptide tissue-specifically stimulated CXCL12 and Hoxa3 differentiation markers in aging human bronchial epithelial cells (Khavinson et al., 2012) - alongside small uncontrolled observational series in chronic respiratory disease (Russian-language literature). It is not FDA- or EMA-approved, not registered as a drug anywhere outside Russia, and not in any major respiratory guideline. Treat it as an experimental bioregulator rather than an established respiratory therapy.
Does Bronchogen actually help with COPD or chronic bronchitis?
The honest answer is: the evidence is thin. Russian uncontrolled observational series report subjective improvements in dyspnoea, cough, and sputum clearance and modest improvements in spirometry after 20-30 day oral cycles. There are no placebo-controlled, blinded randomised trials. The reported improvements are consistent with placebo response, seasonal variation, regression to the mean, or concomitant therapy effects - the study designs cannot distinguish. For evidence-graded COPD management, the priority list is smoking cessation, bronchodilators (2-agonists and muscarinic antagonists), inhaled corticosteroids where indicated, pulmonary rehabilitation, and vaccinations. Bronchogen is a speculative adjunct, not a substitute for these.
What is the correct Bronchogen dose?
Khavinson convention is 20 mg oral/sublingual once daily for 10 consecutive days, with 60-90 day washouts between cycles. Early Russian clinical series used longer 20-30 day courses, but the shorter 10-day cycle is the current recommended standard across the Khavinson tetrapeptide family. The 20 mg capsule contains an undisclosed amount of actual peptide - historical disclosures suggest 2-4 mg AEDL with the balance as excipients. For subcutaneous administration using synthetic lyophilised peptide, 2-5 mg daily for 10 days is the community pattern. Russian clinicians favour autumn entry to precede winter respiratory season, sometimes with a spring repeat. There is no dose-ranging trial establishing that 20 mg oral is optimal.
How does Bronchogen compare to inhalers and evidence-graded respiratory therapies?
Inhaled 2-agonists produce measurable bronchodilation within minutes through a mapped molecular mechanism and have thousands of RCT-validated trials. Inhaled corticosteroids suppress eosinophilic airway inflammation with quantified clinical benefit. Muscarinic antagonists block parasympathetic bronchoconstriction with known receptor kinetics. Bronchogen sits at an entirely different level of mechanistic specification - it is a hypothesis about chromatin modulation with limited replication. For any serious respiratory disease (COPD, asthma, severe allergic rhinitis, bronchiectasis), evidence-graded inhaled and systemic therapy is the foundation. Bronchogen can be an experimental adjunct on top of that foundation; it cannot replace it.
Is Bronchogen safe?
The reported short-term safety profile in Russian literature is mild - occasional nausea, mild headache, rare rash. The total documented human exposure is probably in the low thousands, too small to detect rare serious events. Long-term safety over years of intermittent cycles has not been characterised. Pregnancy, breastfeeding, paediatric use, active lung cancer, and active respiratory infection are absolute or strong contraindications. Use with third-party HPLC-verified product, monitor baseline and post-cycle spirometry if possible, and work with a pulmonologist if you have chronic respiratory disease.
Can I use Bronchogen while on inhaled therapy for asthma or COPD?
From an interaction standpoint, yes - there are no known pharmacokinetic or pharmacodynamic interactions between Bronchogen and inhaled 2-agonists, muscarinic antagonists, or corticosteroids. However, Bronchogen should never substitute for inhaled maintenance therapy. Do not stop or reduce maintenance inhalers to test Bronchogen alone. Continue evidence-graded therapy and treat Bronchogen as an experimental add-on. Notify your pulmonologist of any bioregulator cycles so they have complete information.
How does Bronchogen compare to the other Khavinson peptides?
Bronchogen is the respiratory-focused member of the Khavinson tetrapeptide family, sibling to Pinealon (brain), Thymogen (immune), Vilon (thymus), Livagen (liver), and Epitalon (pineal/general aging). They share the passive-membrane-permeation-plus-chromatin-modulation mechanistic claim. Bronchogen is less frequently published in English-indexed literature than Epitalon or Thymogen, with the core Russian evidence concentrated in respiratory indications. Among the family, Epitalon has the most extensive literature, Thymogen has the most regulatory recognition (registered Russian pharmaceutical), and Bronchogen occupies a narrower niche focused on respiratory conditions.
Can I stack Bronchogen with NAC, mucolytics, or respiratory supplements?
Yes, and this is a common community pattern. NAC 600-1200 mg daily has some evidence for chronic bronchitis symptom reduction and alters mucus disulphide chemistry directly. Combining with Bronchogen is safe from an interaction standpoint. Glutathione precursors, bromelain for post-nasal drip, and standard supportive respiratory supplements layer reasonably alongside bioregulator cycles. Do not use any of these as substitutes for smoking cessation, pulmonary rehabilitation, or clinic-prescribed inhaled therapy.
Where do I source quality Bronchogen?
The supply channel is split: post-Soviet supplement vendors sell 20 mg oral capsules at moderate cost but with variable quality control, and international research-peptide suppliers sell lyophilised synthetic AEDL peptide for reconstitution at higher per-milligram cost. Require third-party HPLC confirmation of peptide content and endotoxin testing from either source. Avoid vendors without certificates of analysis. For subcutaneous administration from reconstituted peptide, ensure you are comfortable with injection technique and sterile procedure. The oral capsule is the conservative default for first-time users.
If I want respiratory support through the BodyHackGuide ad funnel, what is the actual priority list?
For someone arriving via a BodyHackGuide respiratory-health ad, the evidence-graded ranked stack is: (1) smoking cessation if applicable - nothing else matters nearly as much; (2) pulmonary rehabilitation or structured exercise; (3) vaccinations (influenza, pneumococcal, COVID-19, RSV for older adults); (4) clinician-prescribed inhaled therapy for obstructive disease; (5) NAC 600-1200 mg daily for chronic bronchitis symptoms; (6) environmental air quality and allergen reduction; (7) evidence-based biologic therapy for severe asthma phenotypes (benralizumab, mepolizumab, dupilumab); (8) experimental bioregulators like Bronchogen as advanced-protocol add-ons. Use ads to bring in traffic interested in respiratory health, convert to the evidence-graded content pages, and offer Bronchogen as a tier-4+ experimental option for users who have already done the proven work.
How many vendors sell Bronchogen, and what does it cost per mg?
1 of the vendors BodyHackGuide tracks list Bronchogen (1 listing). Among BodyHackGuide's Bronchogen listings recorded as in stock with a milligram count, the lowest price per milligram is $3.95/mg at Ion Peptide and the median is $3.95/mg. The Bronchogen prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Bronchogen listing is dated 22 April 2026.
Which vendors have third-party COAs for Bronchogen on file at BodyHackGuide?
BodyHackGuide holds 4 third-party certificate records for Bronchogen, from . No editor has read any of BodyHackGuide's 4 certificate records for Bronchogen. The laboratory named on BodyHackGuide's Bronchogen certificate records is Freedom Diagnostics Testing, and the newest test date on them is 9 August 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Related
Articles on Bronchogen
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.
